Advanced search
Publication Cover
Acta Cardiologica Volume 78, 2023 - Issue 9
Submit an article Journal homepage
456
Views
5
CrossRef citations to date
0
Altmetric
Review Article

Does the long-term administration of proton pump inhibitors increase the risk of adverse cardiovascular outcomes? A ChatGPT powered umbrella review

Eleftherios Teperikidisa Third Department of Cardiology, Ippokratio General Hospital, Aristotle University of Thessa-loniki, Thessaloniki, Greece;b Clinical Research Unit, Special Unit for Biomedical Research and Education (SUBRE), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceCorrespondence[email protected]
,
Aristi Boulmpoua Third Department of Cardiology, Ippokratio General Hospital, Aristotle University of Thessa-loniki, Thessaloniki, Greece
,
Victoria Potoupnia Third Department of Cardiology, Ippokratio General Hospital, Aristotle University of Thessa-loniki, Thessaloniki, Greece
,
Satyabrata Kunduc Department of Pharmacology, ISF College of Pharmacy, Moga, India
,
Balpreet Singhd Department of Biochemistry, Punjab Agricultural University, Ludhiana, India
&
Christodoulos Papadopoulosa Third Department of Cardiology, Ippokratio General Hospital, Aristotle University of Thessa-loniki, Thessaloniki, Greece
Pages 980-988 | Received 11 Apr 2023, Accepted 26 Jun 2023, Published online: 11 Jul 2023

References

  • Mishuk AU, Chen L, Gaillard P, et al. National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017. J Am Pharm Assoc. 2003;S1544-3191(20)30476-3.
  • Daniels B, Pearson SA, Buckley NA, et al. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. Therap Adv Gastroenterol. 2020;13:1756284820913743. doi:10.1177/1756284820913743.
  • Mazer-Amirshahi M, Mullins PM, van den Anker J, et al. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med. 2014;32(6):618–622. doi:10.1016/j.ajem.2014.03.019.
  • Lee D, Kim JS, Kim BJ, et al. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention. Medicine (Baltimore). 2021;100(52):e27411. doi:10.1097/MD.0000000000027411.
  • Malhotra K, Katsanos AH, Bilal M, et al. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: a systematic review and Meta-Analysis. Stroke. 2018;49(2):312–318. doi:10.1161/STROKEAHA.117.019166.
  • Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton pump inhibitor Drug-Drug interaction and risk of adverse clinical outcomes among PCI-Treated ACS patients: a meta-analysis. JMCP. 2016;22(8):939–947. doi:10.18553/jmcp.2016.22.8.939.
  • Demcsák A, Lantos T, Bálint ER, et al. PPIs are not responsible for elevating cardiovascular risk in patients on Clopidogrel-A systematic review and Meta-Analysis. Front Physiol. 2018;9:1550. doi:10.3389/fphys.2018.01550.
  • Khan MY, Siddiqui WJ, Alvarez C, et al. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(8):847–853. doi:10.1097/MEG.0000000000001125.
  • Guo H, Ye Z, Huang R. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and Meta-Analysis. Front Pharmacol. 2021;12:694698. doi:10.3389/fphar.2021.694698.
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
  • Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. doi:10.1136/bmj.j4008.
  • Nolde M, Ahn N, Dreischulte T, et al. Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2022;106:80–89. doi:10.1016/j.ejim.2022.09.021.
  • Batchelor R, Kumar R, Gilmartin-Thomas JFM, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780–796. doi:10.1111/apt.14955.
  • Farhat N, Fortin Y, Haddad N, et al. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Crit Rev Toxicol. 2019;49(3):215–261. doi:10.1080/10408444.2019.1583167.
  • Sun S, Cui Z, Zhou M, et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. Neurogastroenterol Motil. 2017;29(2):e12926. doi:10.1111/nmo.12926.
  • Yang M, He Q, Gao F, et al. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Med. 2021;19(1):316. doi:10.1186/s12916-021-02180-5.
  • Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27(4):443–450. doi:10.1016/j.hlc.2017.10.020.
  • Li S, Liu F, Chen C, et al. Real-World relationship between proton pump inhibitors and Cerebro-Cardiovascular outcomes independent of clopidogrel. Int Heart J. 2019;60(4):910–918. doi:10.1536/ihj.18-584.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.